TP-1287

• Description :

  TP-1287, a prodrug of Alvocidib (HY-10005), is an orally active CDK9 inhibitor[1].

• UNSPSC :

  12352005

• Target :

  CDK

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/tp-1287.html

• Purity :

  95.10

• Solubility :

  DMSO : 10 mg/mL (ultrasonic; warming; heat to 60°C) |Methanol : 125 mg/mL (ultrasonic)

• Smiles :

  O=P(O)(O)OC1=CC(O)=C(C(C=C(C2=C(C=CC=C2)Cl)O3)=O)C3=C1[C@@H]4[C@@H](CN(CC4)C)O

• Molecular Formula :

  C21H21ClNO8P

• Molecular Weight :

  481.82

• References & Citations :

  [1]Tyagi E, et al. The Oral CDK9 Inhibitor, TP-1287, Is Active in Non-Clinical Models of Multiple Myeloma. Blood, 2018, 132: 3269.|[2]Kim W, et al. TP-1287, an oral prodrug of the cyclin-dependent kinase-9 inhibitor alvocidib. Cancer Research, 2017, 77 (13_Supplement) : 5133-5133.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C (Powder, sealed storage, away from moisture)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 1

• Isoform :

  CDK9

• CAS Number :

  [2044686-42-0]